ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Other Events
Item 8.01.Other Events
On February 23, 2017, Abeona Therapeutics Inc. issued a press
release entitled Abeona Therapeutics Announces Voluntary
Dismissal of Securities Class Action Lawsuit. The full text of
the press release is filed as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
Item 9.01Financial Statements and
Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 |
Press release dated February 23, 2017, entitled Abeona Therapeutics Announces Voluntary Dismissal of Securities Class Action Lawsuit |
About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)
Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard. ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information
ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session down -0.20 at 4.90 with 371,590 shares trading hands.